Tirzepatide was ineffective at mitigating doxorubicin-induced oxidative stress and cardiotoxicity, suggesting not all GLP-1/GIP drug protective effects extend to chemotherapy damage.
Key findingTirzepatide was ineffective at mitigating doxorubicin-induced oxidative stress and cardiotoxicity, s
What the researchers found
Tirzepatide was ineffective at mitigating doxorubicin-induced oxidative stress and cardiotoxicity, suggesting not all GLP-1/GIP drug protective effects extend to chemotherapy damage.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
40 female Wistar rats across four groups. Doxorubicin at 5 mg/kg body weight. Tirzepatide tested as neuroprotective agent.
How the study worked
Methodology in publication.
Who was studied
40 female Wistar rats in a doxorubicin chemotherapy cognitive damage model
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Ineffectiveness of tirzepatide in mitigating Doxorubicin-induced oxidative stress and cognitive deficits in a rat model.
Frontiers in pharmacology, 16, 1638527
Citation
Alolayan, Salma A; Alhowail, Ahmad H. (2025). Ineffectiveness of tirzepatide in mitigating Doxorubicin-induced oxidative stress and cognitive deficits in a rat model.. Frontiers in pharmacology, 16, 1638527. https://doi.org/10.3389/fphar.2025.1638527